Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of “Hold” by Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received an average recommendation of “Hold” from the twenty analysts that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $123.33.

A number of research firms have recently issued reports on ZBH. BTIG Research reduced their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Barclays dropped their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research report on Thursday, December 12th. Raymond James lowered their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Oppenheimer reduced their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday, October 15th. Finally, Evercore ISI dropped their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently made changes to their positions in the company. First Hawaiian Bank raised its holdings in Zimmer Biomet by 14.0% during the 4th quarter. First Hawaiian Bank now owns 20,400 shares of the medical equipment provider’s stock worth $2,155,000 after purchasing an additional 2,500 shares during the last quarter. Nordea Investment Management AB raised its stake in shares of Zimmer Biomet by 3.9% during the fourth quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider’s stock worth $1,732,000 after buying an additional 609 shares during the last quarter. Central Pacific Bank Trust Division lifted its holdings in Zimmer Biomet by 7.4% in the fourth quarter. Central Pacific Bank Trust Division now owns 14,525 shares of the medical equipment provider’s stock valued at $1,534,000 after buying an additional 1,000 shares during the period. GAMMA Investing LLC grew its holdings in Zimmer Biomet by 67.6% during the 4th quarter. GAMMA Investing LLC now owns 2,298 shares of the medical equipment provider’s stock worth $243,000 after acquiring an additional 927 shares during the period. Finally, B. Riley Wealth Advisors Inc. raised its position in shares of Zimmer Biomet by 17.5% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 2,404 shares of the medical equipment provider’s stock valued at $260,000 after acquiring an additional 358 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $101.41 on Friday. Zimmer Biomet has a 52-week low of $100.67 and a 52-week high of $133.90. The firm has a market cap of $20.19 billion, a P/E ratio of 19.28, a PEG ratio of 1.96 and a beta of 1.02. The business’s 50-day moving average price is $108.09 and its 200 day moving average price is $108.05. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.65 earnings per share. As a group, sell-side analysts predict that Zimmer Biomet will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.